What is the share price of Sterling Biotech Ltd (STERLINBIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Sterling Biotech Ltd (STERLINBIO) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Sterling Biotech?

The latest standalone P/E ratio of Sterling Biotech as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Sterling Biotech Ltd (STERLINBIO)?

The latest standalone P/B ratio of Sterling Biotech Ltd (STERLINBIO) as of 01-Jan-1970 is -0.01.

What is the 52-week high and low of Sterling Biotech Ltd (STERLINBIO)?

The 52-week high of Sterling Biotech Ltd (STERLINBIO) is Rs. 0.85 and the 52-week low is Rs. 0.77.

Sterling Biotech Ltd (STERLINBIO) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Sterling Biotech Ltd (STERLINBIO)
Brand: Sterling Biotech

Sterling Biotech Ltd (STERLINBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512299 NSE: STERLINBIO Chemicals | Small Cap | Sterling Biotech Share Price

Sterling Biotech Ltd (STERLINBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512299 NSE: STERLINBIO Chemicals | Small Cap | Sterling Biotech Share Price

Key Metrics

Valuation Multiples

Market Cap

₹21 Cr.

Current Price

₹0

52-Week Low / High

₹1 / 1

TTM EPS

₹-10.9

TTM Sales

₹408 Cr.

Book Value per Share

₹-79.7

P/E Ratio

0.00

Industry PE

Price to Book (P/B)

-0.01

Price to Sales (P/S)

0.05

EV/EBITDA

-166.59

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

-2.17%

Return on Capital Employed (ROCE)

-0.70%

Return on Assets (ROA)

-3.07%

Operating Profit Margin

14.6%

Net Profit Margin

-4.22%

Gross Profit Margin

18.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

5.2%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

12.63%

Net Profit Growth (1 Year)

-100.32%

Asset Quality

Promoter Holding

24.64%

Pledged shares (%) of Promoter's holding (%)

62.29%

Reserves

₹-2,197 Cr.

Equity

₹27.2 Cr.

Face Value

₹1

All Time Low / High

₹0.67 / 262.45

Sterling Biotech stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Dec'11	Dec'12	Dec'13	Dec'14	Mar'16	Mar'17	Mar'18	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	4.6%	-1.7%	-2.9%	-3.1%	-3.6%	-3%	-12.5%	-5.7%	385.8%	-0.7%	-
Value Creation Index ⓘ	-0.7	-1.1	-1.2	-1.2	-1.3	-1.2	-1.9	NA	NA	NA	-
Growth Parameters ⓘ
Sales ⓘ	1,662	835	718	667	419	368	352	410	434	457	408
Sales YoY Gr.	-	-49.8%	-14%	-7.1%	-37.2%	-12.1%	-4.4%	16.3%	6%	5.2%	-
Adj EPS ⓘ	3.2	-13	-15	-16.8	-13.2	-15.2	-17.1	-8.7	2.4	0.1	-10.9
YoY Gr.	-	-503.4%	NA	NA	NA	NA	NA	NA	NA	-97.9%	-
BVPS (₹) ⓘ	93	69.8	54.9	38.1	48.9	46.9	10.1	-210.6	1.4	1.4	-79.7
Adj Net Profit ⓘ	86.5	-349	-401	-458	-360	-412	-465	-236	1,562	33.5	-295
Cash Flow from Ops. ⓘ	370	811	172	256	53.6	1	-32.8	32.4	-15.7	48.8	-
Debt/CF from Ops. ⓘ	11.5	4.5	22.6	18	98	7326.3	-228.4	249	0	0.2	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-13.4%	1.7%	9.1%	5.2%
Adj EPS ⓘ	-37.1%	NA	NA	-97.9%
BVPSⓘ	-37.4%	-51.1%	-48.7%	-2.1%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Dec'11	Dec'12	Dec'13	Dec'14	Mar'16	Mar'17	Mar'18	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	3.5	-16	-24	-22.8	-21.4	-28.1	-59.9	8.7	-64.6	3.8	27.7
Op. Profit Mgn % ⓘ	38.4	17.7	13.2	12	12.3	3.4	4	8.4	13.5	14.6	9
Net Profit Mgn % ⓘ	5.2	-41.8	-55.8	-68.6	-86	-112	-131.9	-57.7	359.6	7.3	-72.4
Debt to Equity ⓘ	1.7	1.9	2.6	1.8	4	5.5	27.2	-1.4	0	0	-
Working Cap Days ⓘ	458	801	742	724	791	1,097	853	284	150	166	47
Cash Conv. Cycle ⓘ	325	630	586	524	504	669	427	92	97	103	-1,606

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Dec'11	Dec'12	Dec'13	Dec'14	Mar'16	Mar'17	Mar'18	Mar'22	Mar'23	Mar'24
Sales	1,661.95	834.77	718.07	666.95	523.99	368.43	352.33	409.88	434.25	456.85
Operating Expenses ⓘ +	1,024.55	687.17	623.39	587.04	459.53	355.85	338.24	459.37	375.49	390.66
Manufacturing Costs	11.07	5.56	11.35	7.69	10.90	6.70	8.35	96.31	109.30	122.91
Material Costs	879.63	580.94	511.84	465.51	354.44	273.46	251.51	202.92	193.44	170.81
Employee Cost	49.37	53.20	54.20	51.31	65.81	54.17	58.33	41.46	43.40	47.88
Other Costs ⓘ	84.48	47.47	46	62.52	28.38	21.52	20.04	118.67	29.35	49.06
Operating Profit ⓘ	637.41	147.60	94.68	79.91	64.46	12.57	14.10	-49.48	58.77	66.19
Operating Profit Margin (%)	38.4%	17.7%	13.2%	12.0%	12.3%	3.4%	4.0%	-12.1%	13.5%	14.5%
Other Income ⓘ +	9.31	7.02	4.26	3.68	7.85	3.98	5.50	4.46	10.05	19.86
Exceptional Items ⓘ	-96.23	-1.22	0	0	0	0	-772.29	0	6,321.37	-76.99
Interest ⓘ	270.43	412.33	437.71	469.51	414.78	369.80	439.67	2.06	0.24	0.72
Depreciation ⓘ	252.22	258.83	254.32	276.57	345.14	263.55	245.75	242.84	158.18	15.27
Profit Before Tax ⓘ	27.83	-517.75	-593.08	-662.49	-687.62	-616.80	-1,438.12	-289.92	6,231.78	-6.93
Tax ⓘ	8.70	-167.98	-192.43	-204.78	-237.15	-204.34	-432.73	5.31	243.07	12.35
Profit After Tax	19.13	-349.77	-400.65	-457.71	-450.47	-412.46	-1,005.39	-295.23	5,988.71	-19.29
PAT Margin (%)	1.2%	-41.9%	-55.8%	-68.6%	-86.0%	-112.0%	-285.0%	-72.0%	1,379.1%	-4.2%
Adjusted EPS (₹)	0.7	-13.1	-15.0	-16.8	-16.6	-15.2	-36.9	-10.9	9.3	-0.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Sterling Biotech - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Dec'11	Dec'12	Dec'13	Dec'14	Mar'16	Mar'17	Mar'18	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund +	2,490.89	1,870.78	1,470.12	2,544.29	1,663.74	1,276.09	275.85	-5,732.54	898.67	879.42
Share Capital ⓘ	26.79	26.79	26.79	1,534.03	27.22	27.22	27.22	27.22	643.35	643.35
Reserves ⓘ	2,464.10	1,843.99	1,443.34	1,010.26	1,636.53	1,248.87	248.64	-5,759.75	255.33	236.07
Debt +	2,732.50	2,609.14	2,640.31	3,042.86	5,098.51	4,949.72	3,189.60	8,064.66	0	10.82
Long Term Debt	1,506.47	1,137.35	947.78	1,861.15	4,166.07	3,991.52	1,978.74	6,820.37	0	0
Short Term Debt	1,226.03	1,471.79	1,692.52	1,181.71	932.44	958.20	1,210.87	1,244.28	0	10.82
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	43.88	26.50	20.05	24.69	22.33	37.90	20.70	26.87	22.64	31.94
Others Liabilities ⓘ	1,867.20	2,577.26	3,222.75	1,350.32	1,395.56	1,711.80	3,578.13	-472.25	-301.36	-285.64
Total Liabilities ⓘ	7,134.47	7,083.68	7,353.24	6,962.16	8,180.15	7,975.51	7,064.29	1,886.74	619.95	636.53
Fixed Assets
Net Fixed Assets ⓘ +	2,942.10	3,633.13	3,433.44	3,273.84	2,964.55	2,726.29	2,488.12	1,518.24	309.21	261.10
Gross Block	3,922.07	4,871.93	4,926.18	5,021.26	3,283.48	3,287.53	3,295.10	3,301.69	805.93	826.29
Accumulated Depreciation	979.97	1,238.80	1,492.74	1,747.42	318.92	561.24	806.98	1,783.45	496.72	565.20
CWIP ⓘ	1,645.51	1,551.81	2,109.79	2,270.13	2,449.75	2,442.30	2,503.20	0	0.11	14.47
Investments ⓘ	365	376.52	376.52	168.91	1,552.44	1,582.07	1,586.45	3.37	3.53	1.13
Inventories	1,008.79	869.94	793.52	634.57	717.53	703.30	60.93	92.43	95.60	122.51
Trade Receivables	723.01	347.10	335.71	180.56	42.25	43.33	51.34	35.90	49.98	52.67
Cash Equivalents ⓘ	21.99	17.83	17.49	17.66	16.64	16.93	13.28	198.35	165.14	202.41
Others Assets ⓘ	428.07	287.35	286.78	416.50	436.99	461.29	360.96	38.45	-3.62	-17.75
Total Assets ⓘ	7,134.47	7,083.68	7,353.24	6,962.16	8,180.15	7,975.51	7,064.29	1,886.74	619.95	636.53

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Dec'11	Dec'12	Dec'13	Dec'14	Mar'16	Mar'17	Mar'18	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ +	369.72	811.26	171.87	255.89	67.03	0.95	-32.81	32.39	-15.69	48.84
PBT ⓘ	124.06	-516.54	-593.08	-662.49	-687.62	-616.80	-665.82	-289.92	6,231.78	-6.93
Adjustment ⓘ	527.53	672.38	692.02	777.40	759.93	633.35	683.32	325.67	-6,171.17	79.12
Changes in Working Capital ⓘ	-146.26	656.78	74.05	172.29	1.44	-15.6	-50.3	-3.37	-75.48	-21.58
Tax Paid ⓘ	-39.38	-0.14	-1.12	-31.33	-6.71	0	0	0	-0.82	-1.76
Cash Flow From Investing Activity ⓘ +	-733.24	-811.63	-314.82	17.20	-84.45	-49.28	-9.15	1.15	-119.22	-98.28
Capex	-732.17	-800.11	-314.82	-190.41	-84.39	-49.28	-9.42	-2.68	-4.70	-36.19
Net Investments	-1.07	-11.51	0	207.61	-0.07	0	0	0	0	0
Others ⓘ	-0	0	0	0	0	0	0.27	3.83	-114.53	-62.09
Cash Flow From Financing Activity ⓘ +	227.14	-3.79	142.60	-272.92	16.40	48.62	38.44	54.84	4.56	9.86
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	643.35	0
Net Proceeds from Borrowing ⓘ	327.03	267.83	408.35	-917.42	243.86	357.55	-27.70	0	-638.70	0
Interest Paid ⓘ	-270.43	-412.33	-437.71	-469.51	-414.78	-369.80	0	0	-0	-0.07
Dividend Paid ⓘ	-13.39	0	0	0	0	0	0	0	0	0
Others ⓘ	183.93	140.71	171.96	1,114.01	187.32	60.86	66.14	54.84	-0.08	9.93
Net Cash Flow ⓘ	-136.38	-4.15	-0.35	0.17	-1.02	0.29	-3.52	88.38	-130.35	-39.58

Financial Ratio

PARTICULARS	Dec'11	Dec'12	Dec'13	Dec'14	Mar'16	Mar'17	Mar'18	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	0.77	-16.04	-23.98	-36.51	-33.35	-28.06	-129.56	N/A	0	-2.17
ROCE (%)	4.6	-1.72	-2.86	-3.09	-3.55	-3	-12.49	N/A	385.79	-0.7
Asset Turnover Ratio	0.24	0.12	0.1	0.09	0.07	0.05	0.05	0.09	0.35	0.73
PAT to CFO Conversion(x)	19.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-0	N/A
Working Capital Days
Receivable Days	153.70	234	173.50	141.30	72.50	39	48	38.80	36.10	41
Inventory Days	186.10	410.70	422.80	390.80	440.20	648	387.70	68.30	79	87.10
Payable Days	19.50	22.10	16.60	17.50	24.20	40.20	42.50	42.80	46.70	58.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

62.29

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sterling Biotech Ltd FAQs

The current trading price of Sterling Biotech on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sterling Biotech stood at ₹20.96 Cr

The latest P/E ratio of Sterling Biotech as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Sterling Biotech as of 31-Dec-1969 is -0.01.

The 52-week high of Sterling Biotech is ₹0.85 and the 52-week low is ₹0.77.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sterling Biotech is ₹408 ( Cr.) .

Data is not available for this company.

The key valuation ratios of Sterling Biotech Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

No data found

About Sterling Biotech Ltd

Working with and developing any opportunity into reality is a mindset at Sterling Group. Sterling Biotech Limited with its new thinking, new capabilities and sense of urgency aspires to “Earn trust, every moment” of its partners, collaborators, stake holders and customers.

The company is focusing to commercialize Active Pharmaceutical Ingredient (API) and make it available at competitive prices to its global customers.

The company’s capabilities include state of art research centre, advance pilot plant for scale up studies, modern facility of bioreactors and range of down streaming process equipments. All these are coupled with dedicated and qualified work force, well equipped quality control laboratory and quality assurance systems

The company strives to become leaders in API pharmaceutical area by developing state of the art facility for research and development, contract manufacturing of active pharmaceutical ingredients. It builds quality in every aspect of manufacturing with particular laid down emphasis based on current Good Manufacturing Practices.

The company is committed to scaling new heights and creating new dimensions in Fermentation based API and Synthetic API. This way it shall support aspiration to “Live better and Live longer”.

The company’s manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting CEP for the active pharmaceutical ingredient Epirubicin, Lovastatin

This adequately reflects Sterlings commitment towards quality. Efforts to attain such standards have also opened the key to gain foothold in the regulated and semi regulated markets throughout US and Europe

Business area of the company

The company is engaged in the manufacturing of Pharma Grade Gelatine & Di-Calcium Phosphate and other Pharma products. The Company has presence in both domestic and international markets.

Products

Simvastatin Ammonium Salt
Lovastatin
Daunorubicin HCL
Doxorubicin HCL
Epirubicin HCL
Idarubicin HCL
Zoledronic Acid

Sterling Biotech Ltd (STERLINBIO)

Sterling Biotech Ltd (STERLINBIO)

Sterling Biotech stock performance

10 Year X-Ray :